Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Viking Therapeutics Inc
VKTX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$26.71
1.66
6.63%
Últ. Act.: Oct 21, 5:17 AM
$26.67
1.62
6.47%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Viking Therapeutics Financials
Viking Therapeutics (VKTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq 100 Flirts with Records, Oil Sinks for Fifth Day: Stock Market Today
Nasdaq 100 printed an intraday record on AI enthusiasm while financials slid nearly 2% and crude fell for a fifth straight session.
Piero Cingari
Viking Therapeutics Stock Moves Lower: What's Going On?
Viking Therapeutics Inc (NASDAQ:VKTX) shares are retreating Thursday despite reporting a narrower second-quarter loss than expected. Here's what you should know.
Evette Mitkov
PRO
Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.10) per share which beat the analyst consensus estimate of $(1.25) by 12 percent. This is a 89.66 percent decrease over losses of $(0.58) per share from
Benzinga Newsdesk
PRO
Viking Therapeutics Q1 EPS $(1.37) Misses $(1.02) Estimate
Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.02) by 34.31 percent. This is a 234.15 percent decrease over losses of $(0.41) per share
Benzinga Newsdesk
Earnings Scheduled For April 29, 2026
Benzinga Insights
Viking Therapeutics Stock Soars: What's Driving The Momentum?
Viking Therapeutics (NASDAQ:VKTX) stock is soaring on Thursday, extending the momentum it picked up in Wednesday's after‑hours session following the company's fourth‑quarter earnings release.
Evette Mitkov
